Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AstraZeneca) D0816L00003 / LIGHTNon-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior
Lines of Chemotherapy
Helpman, Dr LimorOpen to recruitmentNCT02983799
(CCTG) OV.25 / STICs AND STONEsA Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs)Bordeleau, Dr LouiseOpen to recruitmentNCT03480776
(UHN) NECO / NECA Phase II, Open label Study of the Poly(ADP-ribose) Polymerase Inhibitor Niraparib (MK 4827) in Recurrent Endometrial CancerJimenez, Dr WaldoOpen to recruitmentNCT03016338
(ImmunoGen) IMGN853-0402A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults with Folate Receptor
Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Hirte, Dr HalSuspended/On holdNCT02606305
(UHN) PHL-086/NCI 9322A Phase II Study of XL-184 (Cabosantinib) In Recurrent or Metastatic Endometrial CancerHirte, Dr HalSuspended/On holdNCT01935934
Download PDF